- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01196312
Anxiety Sensitivity Treatment for Heroin Users (ASTH-HR)
May 25, 2023 updated by: Joe Smith, University of Maryland, College Park
Novel Intervention for Drug Use and HIV Risk Among Anxiety Sensitive Heroin Users
Anxiety Sensitivity Treatment for Heroin Users is a development project targeting mild and above levels of anxiety sensitivity that will involve the testing of a specialized protocol for improving treatment retention and outcomes for heroin dependent individuals in a residential substance use treatment.
ASTH-HR will integrate established treatment modules such as Healthy Relationships, along with interoceptive exposure, affect management, and psycho-education exercises developed for anxiety prevention and treatment programs with standard substance use treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20002
- Salvation Army Harbor Light Treatment Facilitiy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- exhibit a score of 21 on a self-report measure of anxiety sensitivity
- be in 28 days of residential substance use treatment.
- meet criteria for current opioid dependence as determined by SCID interview administered at intake.
Exclusion Criteria:
- evidence of limited mental competency
- the inability to give informed, voluntary, written consent to participate
- current psychosis
- current bipolar disorder.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anxiety Sensitivity Index-3
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Timeline Follow Back 90 days
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
August 23, 2010
First Submitted That Met QC Criteria
September 3, 2010
First Posted (Estimated)
September 8, 2010
Study Record Updates
Last Update Posted (Actual)
May 30, 2023
Last Update Submitted That Met QC Criteria
May 25, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DA023384
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Consciousness and Healing InitiativeNot yet recruitingAnxiety | Anxiety State | Mental Health Issue | Anxiety Generalized
-
Saglik Bilimleri UniversitesiRecruiting
Clinical Trials on Anxiety sensitivity therapy
-
Ohio UniversityCompletedAnxiety | Anxiety SensitivityUnited States
-
Florida State UniversityCompleted
-
VA Office of Research and DevelopmentRecruiting
-
University of VermontNational Institute on Drug Abuse (NIDA)Completed
-
Florida State UniversityCompletedExperimental | Placebo ContolUnited States
-
Florida State UniversityCompleted
-
Hartford HospitalCompletedOther (or Unknown) Substance Use DisordersUnited States
-
University of HoustonCompletedObesity | Physical Activity | Eating | Anxiety SensitivityUnited States
-
Southeast Louisiana Veterans Health Care SystemSouth Central Mental Illness Research, Education & Clinical CenterCompletedOpioid Use DisorderUnited States
-
Florida State UniversityOhio State University; Ohio UniversityRecruitingDementia | Anxiety | Alzheimer Disease | Mild Cognitive ImpairmentUnited States